EMA/654877/2017

European Medicines Agency decision

P/0313/2017

of 30 October 2017

on the acceptance of a modification of an agreed paediatric investigation plan for febuxostat (Adenuric), (EMEA-001417-PIP01-12-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0313/2017

of 30 October 2017

on the acceptance of a modification of an agreed paediatric investigation plan for febuxostat (Adenuric), (EMEA-001417-PIP01-12-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0117/2014 issued on 6 May 2014 and P/0285/2015 issued on 27 November 2015,

Having regard to the application submitted by Menarini International Operations Luxembourg S.A. on 23 June 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 September 2017, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for febuxostat (Adenuric), film-coated tablet, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Menarini International Operations Luxembourg S.A., 1 Avenue de la Gare, L-1611 – Luxembourg, Luxembourg.

EMA/PDCO/429160/2017
London, 15 September 2017

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001417-PIP01-12-M03

Scope of the application

Active substance(s):

Febuxostat

Invented name:

Adenuric

Condition(s):

Treatment of hyperuricaemia

Prevention of hyperuricaemia

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Menarini International Operations Luxembourg S.A.

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Menarini International Operations Luxembourg S.A. submitted to the European Medicines Agency on 23 June 2017 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0117/2014 issued on 6 May 2014 and P/0285/2015 issued on 27 November 2015.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 18 July 2017.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of hyperuricaemia

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- film-coated tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

1.2. Condition:

Prevention of hyperuricaemia

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- for film-coated tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of hyperuricaemia

2.1.1. Indication(s) targeted by the PIP

Prevention or treatment of hyperuricaemia in children at intermediate or high risk of Tumour Lysis Syndrome (TLS) affected by hematologic malignancies

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1:** Development of an age-appropriate oral solid dosage form.
Non-clinical studies	3	**Study 2:** Dose-range finding juvenile toxicity study in rats. **Study 3:** Definitive juvenile toxicity study in rats aged 6 weeks at study start. **Study 4:** Definitive juvenile toxicity study in rats aged 21 days at study start.
Clinical studies	1	**Study 5:** Open-label, multi-centre, parallel group study to compare the pharmacokinetics (PK), pharmacodynamics (PD) and safety of febuxostat between paediatric patients from 6 to less than 18 years of age and adults.
Extrapolation, modelling and simulation studies	1	**Study 6:** PK/PD modelling and simulation analysis.

2.2. Condition:

Prevention of hyperuricaemia

2.2.1. Indication(s) targeted by the PIP

Prevention or treatment of hyperuricaemia in children at intermediate or high risk of Tumour Lysis Syndrome (TLS) affected by hematologic malignancies

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Film-coated tablet

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1:** Same as for condition: treatment of hyperuricaemia.
Non-clinical studies	3	**Study 2:** Same as for condition: treatment of hyperuricaemia. **Study 3:** Same as for condition: treatment of hyperuricaemia. **Study 4:** Same as for condition: treatment of hyperuricaemia.
Clinical studies	1	**Study 5:** Same as for condition: treatment of hyperuricaemia.
Extrapolation, modelling and simulation studies	1	**Study 6:** Same as for condition: treatment of hyperuricaemia.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of hyperuricaemia

Authorised indication(s):

- Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). ADENURIC is indicated in adults.
- Treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).

2. Prevention of hyperuricaemia

Authorised indication(s):

- Prevention of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use